Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.59% | -55.88% | -60.16% | -76.29% | -74.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.59% | -55.88% | -60.16% | -76.29% | -74.60% |
| Cost of Revenue | -1.16% | -10.52% | -18.93% | -4.02% | -3.79% |
| Gross Profit | -1.42% | 6.67% | 14.07% | -13.32% | -15.33% |
| SG&A Expenses | -9.25% | -10.40% | -19.01% | -24.37% | -23.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.15% | -10.50% | -18.95% | -9.77% | -9.55% |
| Operating Income | 1.31% | 7.60% | 15.41% | -0.96% | -2.00% |
| Income Before Tax | 81.76% | -12.35% | 2.23% | 46.45% | -50.64% |
| Income Tax Expenses | -5.14% | 13.50% | 63.21% | -55.13% | -58.36% |
| Earnings from Continuing Operations | 81.56% | -12.36% | 2.05% | 46.52% | -49.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.56% | -12.36% | 2.05% | 46.52% | -49.65% |
| EBIT | 1.31% | 7.60% | 15.41% | -0.96% | -2.00% |
| EBITDA | 1.22% | 7.41% | 15.29% | -1.51% | -2.66% |
| EPS Basic | 93.48% | 6.14% | 39.18% | 68.40% | 47.85% |
| Normalized Basic EPS | 93.61% | 5.06% | 38.83% | 67.98% | 47.17% |
| EPS Diluted | 58.89% | -48.07% | 4.14% | 46.02% | 47.85% |
| Normalized Diluted EPS | 92.76% | 3.72% | 37.96% | 67.42% | 47.17% |
| Average Basic Shares Outstanding | 57.68% | 48.51% | 62.14% | 84.13% | 144.38% |
| Average Diluted Shares Outstanding | 58.83% | 49.72% | 63.63% | 86.22% | 144.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |